1 The EIC Accelerator Project

EIC Accelerator Program: An Overview

The EIC Accelerator program, part of the European Innovation Council (EIC), specifically targets startups and small to medium-sized enterprises (SMEs) that are developing groundbreaking innovations, particularly in the deep tech sector. It aims to bridge the gap between research and market uptake by providing financial support, mentorship, and access to networks, thus fostering a robust ecosystem for innovation in Europe. The EIC Accelerator is designed to stimulate the creation of high-impact companies that can drive economic growth and technological advancement in Europe.

Funding Structure

The EIC Accelerator offers two primary forms of funding: grants and equity financing.

Role in the European Ecosystem

The EIC Accelerator plays a pivotal role in the European deep tech and startup ecosystem by acting as a catalyst for innovation. It seeks to identify and support high-potential companies that can address significant societal challenges, such as healthcare, climate change, and digital transformation. By providing both financial resources and strategic guidance, the EIC Accelerator enables startups to scale effectively, enhancing their chances of success in a competitive marketplace. Moreover, the program encourages collaboration between innovative companies and established players in various sectors, facilitating knowledge transfer and partnership opportunities.

Endoron Medical Ltd. and the Aortoseal Project

Endoron Medical Ltd., an Israeli startup, emerged as a winner of the EIC Accelerator program with its project, Aortoseal. The project was aimed at developing a minimally invasive and durable endograft fastening solution specifically designed for treating Abdominal Aortic Aneurysms (AAA). The company submitted its Step 2 proposal on June 15, 2022, and successfully advanced to the Step 3 interview, ultimately securing funding for its innovative approach.

Project Overview: Aortoseal

Aortoseal addresses a critical need in the medical field, particularly in the treatment of AAA, which is a life-threatening condition characterized by the ballooning of the abdominal aorta. Traditional surgical methods can be invasive and carry significant risks. Aortoseal aims to provide a safer, less invasive alternative that enhances patient outcomes.

Technology Basics and Background

Aortoseal utilizes advanced materials and cutting-edge engineering to create an innovative fastening mechanism for endografts. The technology focuses on providing a reliable solution that ensures the secure placement of endografts within the aorta, thereby reducing the risk of complications such as graft migration or leakage.

The endograft fastening solution is designed to be minimally invasive, which means it can be deployed through small incisions, significantly reducing recovery time and minimizing the physiological stress on patients. Given the increasing prevalence of AAA, driven by factors such as aging populations and lifestyle diseases, the demand for effective and safe treatment methods is growing.

Endoron Medical's approach is backed by extensive research and development, focusing on biocompatibility and durability. The materials used in Aortoseal are engineered to withstand the dynamic environment of the vascular system while ensuring optimal integration with the body’s tissues.

Conclusion

The EIC Accelerator program serves as a vital platform for innovative startups like Endoron Medical Ltd., facilitating the development and scaling of transformative technologies. Through its structured funding options and support mechanisms, the program enables companies to navigate the complexities of bringing groundbreaking solutions to market. Aortoseal exemplifies the potential of such innovations in addressing critical medical challenges, underlining the importance of investment in deep tech and healthcare solutions within the European ecosystem.

2 The Funding Rounds

Endoron Medical Ltd. (Israel): Financing and Funding History Since EIC Accelerator Award

EIC Accelerator Grant (2022)
Endoron Medical Ltd., based in Israel, was selected as one of 75 winners out of nearly 1,000 applicants in the June 2022 EIC Accelerator cut-off. The company was awarded a €2.5 million grant by the European Commission under this highly competitive program. The funding aimed to accelerate development and clinical validation of Endoron’s Aortoseal® endovascular fastening solution for abdominal aortic aneurysms (AAA).

Series A Funding Round ($10 Million – July 2024)
In July 2024, Endoron Medical successfully closed a $10 million Series A funding round. The round was led by Sofinnova Partners, a leading European life sciences investor, with significant matching contributions from the European Innovation Council Fund (EIC Fund). This investment is being used to accelerate clinical validation of their flagship catheter-based endostapling system, Aortoseal®, including progress through FDA-approved Investigational Device Exemption (IDE) Early Feasibility Studies.

Timeline and Amounts

• June 15, 2022: Submitted Step 2 proposal for EIC Accelerator; later awarded at Step 3 interview.
• November 14, 2022: Public announcement of €2.5M grant from EC via EIC Accelerator.
• July 9–10, 2024: Announced closing of $10M Series A equity round led by Sofinnova Partners with participation from EIC Fund.

Investors

• Sofinnova Partners: Lead investor in the Series A round; brings extensive operational experience supporting high-growth medtech companies.
• European Innovation Council Fund (EIC Fund): Participated with matching investment alongside Sofinnova Partners in both equity and prior non-dilutive grant support.

Company Valuation

As of July 2024 estimates from Dealroom.co:

Enterprise Valuation: $40–60 million following completion of the Series A round.

Use of Funds & Strategic Impact

The funds raised since winning the EIC Accelerator have enabled Endoron Medical to: - Advance their flagship product through key clinical trials and regulatory milestones.

• Scale up operations for wider market entry across Europe and pursue U.S. FDA clearance via IDE studies.
• Position itself at the forefront of minimally invasive AAA repair technologies aiming to become next-generation standard-of-care solutions.

Exit Events: IPO or Acquisition Activity

No exit events—such as IPOs or acquisitions—have been reported for Endoron Medical as of May 1st, 2025. The company remains privately held and focused on product development and validation stages.

---

Summary Table: Key Financing Rounds

Date	Round	Amount	Investors	Notes
Nov. 14 2022	EC Grant	€2.5 million	European Commission/EIC	Non-dilutive grant
Jul. 9–10 24	Series A	$10 million	Sofinnova Partners; EIC Fund	Equity investment

---

Sources

• Endoron raises $10M for abdominal aortic aneurysm stapler
• Endoron raises $10M for Aortoseal AAA repair device - BioWorld
• Endoron Medical raises $10 Million in Series A funding led by Sofinnova Partners - BusinessWire
• Endoron Medical awarded €2.5M grant from European Commission through prestigious EIC Accelerator Program - Sofinnova Partner News

-Dealroom profile: Endoron Medical

-Strata.team – June 22 EIC Accelerator winners & statistics

3 The Press Releases

Endoron Medical Ltd.: Advancing Endovascular Repair Solutions with EIC Accelerator Support Israel-based Endoron Medical, specializing in endograft stapling technology for abdominal aortic aneurysm (AAA) repair, has made significant strides since securing European Innovation Council (EIC) Accelerator funding. The company recently announced a $10 million Series A funding round led by Sofinnova Partners, with matching contributions from the EIC Fund. This follows a previous €2.5 million ($2.7 million) grant awarded under the EIC Accelerator program.

Key Developments

• Technology: Endoron’s catheter-based Aortoseal device uses an endostapling mechanism to seal and anchor endografts during minimally invasive AAA repairs, reducing complications like migration and endoleaks. This addresses critical challenges in complex procedures, potentially lowering reliance on high-risk open surgeries.
• Clinical Progress: The funds are accelerating an FDA-approved Investigational Device Exemption (IDE) Early Feasibility Study (EFS), positioning Aortoseal for clinical validation ahead of commercialization.
• Strategic Partnerships: Sofinnova Partners’ involvement underscores confidence in Endoron’s potential to revolutionize AAA repair, while EIC Fund participation emphasizes alignment with European market expansion goals.

Team & Milestones

Founded in 2019 by CEO Ronit Harpaz (formerly of Bendit Technologies), vascular surgeon Prof. Ron Karmeli, and engineer Eyal Teichman, the company has progressed rapidly through seed financing (2021) to IDE-approved trials.

---

Sources

• Endoron Medical raises $10 Million in Series A funding led by Sofinnova Partners
• Endoron Medical raises US$10 million in Series A funding
• Endoron Medical raises $10M for abdominal aortic aneurysm stapler
• Endoron's Aortoseal Clinical Development Supported by Funding Round
• Endoron Medical nets $10 million for lifesaving aneurysm repair innovations

The company's website (endoronmedical.com) was not directly cited due to unavailable content from provided sources; all information derives from third-party press releases dated July 9–11, 2024.

Note: Press releases or blog posts directly from Endoron’s website/social media were not located within the provided search results.

4 The Technology Advancements

Endoron Medical Ltd.: Current Capabilities and Advancements

Endoron Medical Ltd., an Israeli medtech company, specializes in developing innovative endograft stapling solutions for the endovascular repair of abdominal aortic aneurysms (AAA). The company's flagship product, Aortoseal, is a catheter-based EndoStapling solution designed to address the challenges of sealing and securing endografts in complex procedures.

Advancements Since EIC Accelerator Funding

Following the receipt of the €2.5 million grant from the European Innovation Council (EIC) Accelerator program in November 2022, Endoron Medical has made significant advancements. The grant enabled the company to accelerate the development and clinical validation of its Aortoseal implant, which is crucial for providing long-term durability to endovascular aneurysm repairs (EVAR).

In July 2024, Endoron Medical successfully closed a $10 million Series A funding round led by Sofinnova Partners, with substantial contributions from the European Innovation Council Fund. This funding is aimed at accelerating the clinical validation of Aortoseal through an FDA-approved Early Feasibility Study.

Improvements and New Features

Endoron's technology focuses on ensuring complete sealing and fixation of endografts using a smart stapling mechanism that mimics the effect of surgical anastomosis. The Aortoseal device is designed for simple and fast deployment, providing 360° simultaneous fixation and transmural attachment to the adventitial layer for tight sealing. This technology is particularly beneficial for patients with short or complicated neck anatomies, reducing the need for invasive surgeries.

Demonstration and Clinical Trials

The company is currently engaged in clinical trials as part of its IDE-approved Early Feasibility Study. This study is crucial for demonstrating the efficacy and safety of the Aortoseal device in the market. The participation of the European Innovation Council Fund further emphasizes the commitment to bringing this innovation to the European market.

Patents and Scientific Studies

While specific new patent filings or scientific studies published by Endoron Medical since the EIC funding are not detailed in the available information, the company's advancements are highlighted through its successful funding rounds and ongoing clinical trials. The EIC Accelerator grant and subsequent Series A funding have been instrumental in supporting the development and validation of the Aortoseal technology.

Conclusion

Endoron Medical Ltd. has demonstrated significant progress in developing its Aortoseal technology since receiving the EIC Accelerator funding. The company's focus on clinical validation and market readiness positions it well to address critical challenges in AAA repair.

Sources

• Endoron Medical raises $10 Million in Series A funding led by Sofinnova Partners
• Endoron's Aortoseal Clinical Development Supported by Funding Round
• Endoron Medical
• Endoron Medical awarded a €2.5M grant from the European Commission through the prestigious EIC Accelerator program
• Endoron raises $10M for Aortoseal AAA repair device
• Endoron Medical raises US$10 million in Series A funding
• Endoron Staples Down $10M To 'Revolutionize' Abdominal Aortic Aneurysm Repair
• Endoron Medical Raises $10M in Series A Funding
• Endoron Medical nets $10 million for lifesaving aneurysm repair innovations

5 The Partnerships and Customers

Endoron Medical Ltd. Strategic Partnerships and Market Positioning Since receiving EIC Accelerator funding in June 2022, Endoron Medical has solidified key partnerships to advance its endovascular repair technology for abdominal aortic aneurysms (AAA). Below is an analysis of its collaborations and market trajectory:

---

Key Partnerships

• Role: Lead investor in the $10M Series A round (July 2024), providing capital and operational expertise via its MD Start accelerator.
• Impact: Accelerates clinical validation of Endoron’s Aortoseal device through IDE-approved Early Feasibility Studies (EFS).

• Role: Matching contributor to the Series A round.
• Purpose: Supports commercialization in Europe, targeting complications like endoleaks and graft migration.

• Role: Chairman of the Board since February 2023, leveraging his CoreValve innovation experience.
• Strategic Value: Enhances clinical credibility and guides regulatory strategy for AAA repair solutions.

---

Customer Base & Market Positioning

• While specific customers remain undisclosed due to ongoing trials, Endoron targets vascular surgeons specializing in AAA repair using minimally invasive techniques.
• The company aims to replace high-risk open surgeries by improving endograft sealing—a critical need for patients with complex anatomies (~42% of AAA cases).

---

Strategic Outlook

• Technology Advancement: Sofinnova’s MD Start provides hands-on mentorship to refine manufacturing scalability and clinical protocols. The EIC Fund reinforces EU market access ahead of regulatory milestones like CE marking.
• Market Expansion: Partnerships position Endoron as a disruptor in the global EVAR market ($2B+ segment) by addressing long-term durability challenges in endografts.

---

Sources:

• Endoron Medical raises $10M Series A | Business Wire (2024)
• Vascular News Coverage | VascularNews.com (2024)
• Sofinnova Partners Portfolio Page | Sofinnova Partners
• Prof. Séguin Joins Board | EV Today (2023)

6 The Hiring and Company Growth

Endoron Medical's Team Growth and Development Post-EIC Accelerator Funding Since securing EIC Accelerator funding in 2022, Endoron Medical has advanced its mission to improve endovascular aneurysm repair (EVAR) outcomes through its Aortoseal EndoStapling technology. While specific headcount figures remain undisclosed publicly, the company’s recent $10 million Series A funding round (July 2024), co-led by Sofinnova Partners and the EIC Fund, signals accelerated hiring to support clinical validation and commercialization efforts.

Key Developments in Team Structure

• Leadership Additions: In 2023, Prof. Jacques Séguin—a pioneer in transcatheter aortic valve replacement (TAVR)—joined as Chairman of the Board, strengthening governance for regulatory and clinical milestones.
• Operational Support: Cécile Dupont of Sofinnova Partners MD Start joined Endoron’s management team to provide strategic expertise during its growth phase.
• Founding Team Stability: The core leadership—CEO Ronit Harpaz (ex-Bendit Technologies), CMO Prof. Ron Karmeli (vascular surgery expert), and CTO Eyal Teichman—remains intact since the company’s 2019 founding.

Scaling Through Strategic Hiring
While exact hiring numbers are unavailable, the Series A funding will likely drive recruitment across:

• Clinical Operations: To advance the IDE-approved Early Feasibility Study for Aortoseal.
• R&D/Engineering: Enhancing catheter-based stapling solutions for complex AAA anatomies.
• Regulatory Affairs: Preparing for CE Mark and FDA submissions post-clinical validation.

The influx of capital positions Endoron to address a critical market gap: ~400,000 annual AAA patients in the U.S. and Europe face risks from endoleaks and graft migration due to anatomical complexities—a challenge Aortoseal aims to mitigate through transmural staples that mimic surgical anastomosis.

---

Sources

• Endoron Medical raises US$10 million in Series A funding
• Series A announcement via BusinessWire
• Endoron Medical website

-- Sofinnova Partners portfolio page -- $10M funding coverage by Calcalistech --

7 The Media Features and Publications

Endoron Medical Ltd.: Media Coverage and Public Engagement Post-EIC Accelerator Funding

Endoron Medical Ltd., an Israeli medtech innovator specializing in endovascular repair solutions for abdominal aortic aneurysms (AAA" class="inline-link" target="_blank" rel="noopener noreferrer">Prof. Jacques Séguin appointment announcement, has garnered significant media attention and institutional recognition since securing a €2.5 million EIC Accelerator grant in late 2022. Below is a detailed overview of its public presence, including media features, publications, and event participation.

---

Media Features and Publications

• Business Wire: Highlighted Endoron’s $10 million Series A funding round led by Sofinnova Partners, emphasizing the acceleration of clinical validation for its Aortoseal® EndoStapling solution.
• Vascular News: Detailed the company’s focus on preventing endograft migration and reducing open surgeries through its catheter-based stapling technology.
• Medical Device Network: Reported on the dual financial support from Sofinnova Partners and the EIC Fund, linking it to ongoing IDE-approved Early Feasibility Studies.
• BioWorld: Covered the Series A financing as pivotal for advancing AAA repair innovation, specifically noting Aortoseal®’s potential to address long-term complications in minimally invasive procedures.

---

Podcasts or Interviews

No publicly available podcasts or interviews featuring Endoron’s leadership were identified in recent records. However, CEO Ronit Harpaz has been quoted extensively in press releases discussing clinical milestones and investor partnerships.

---

Conference Participation & Events

While explicit conference attendance is not documented:

• The company’s participation in MedTech Innovator accelerator programs (2022) suggests engagement with industry networking events.
• Collaboration with EU institutions via the EIC Fund implies involvement in European innovation forums or pitch events aligned with grant initiatives.

---

EIC Accelerator Involvement

Endoron was selected among 75 companies out of nearly 1,000 applicants for the EIC Accelerator grant in November 2022. The funds supported scale-up activities for Aortoseal®, aiming to establish it as a standard-of-care solution for complex AAA repairs. Subsequent Series A funding ($10 million) included matching contributions from the EIC Fund, reflecting continued EU confidence in its technology.

---

Sources Used:

• Endoron Medical raises $10 Million - Business Wire (Jul 2024).
• Series A funding announcement - Vascular News (Jul 2024).
• Aortoseal development update - MassDevice (Jul 2024).
• $10M financing coverage - Calcalistech (Jul 2024).
• rahmen-des-reno*725528" class="inline-link" target="_blank" rel="noopener noreferrer">EIC Accelerator grant details - AccessWire (Nov 2022).